Evidence map›Paper›PMID 39945436›Full record

ArticleFuture oncology (London, England)2025

Oncologists' and urologists' preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment.

Caroline Vass, Cathy Anne Pinto, Kelley Myers, Kentaro Imai, Cooper Bussberg, Rituparna Bhattacharya, Shawna R Calhoun, Christine Poulos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Caroline VassHealth Preference Assessment, RTI Health Solutions, Manchester, UK.
Cathy Anne PintoMRL, Merck & Co. Inc, Rahway, NJ, USA.
Kelley MyersHealth Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA.
Kentaro ImaiMRL, Merck & Co. Inc, Rahway, NJ, USA.
Cooper BussbergHealth Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA.
Rituparna BhattacharyaMRL, Merck & Co. Inc, Rahway, NJ, USA.
Shawna R CalhounMRL, Merck & Co. Inc, Rahway, NJ, USA.ORCID 0000-0003-2990-2369
Christine PoulosHealth Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA.ORCID 0000-0001-7810-3411

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo quantify physicians' preferences for adjuvant renal cell carcinoma (RCC) treatments. MATERIALS AND

methodsA discrete-choice experiment was administered online to board-certified/eligible physicians. Physicians chose between pairs of hypothetical adjuvant therapies for a high-risk patient who had recently undergone a radical nephrectomy. Data were analyzed using random-parameters logit and latent-class models.

resultsPhysicians (

conclusionsMost physicians in this study would recommend adjuvant therapy to a typical high-risk postnephrectomy RCC patient.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsOncologistsPractice Patterns, Physicians'UrologistsAdultAgedAttitude of Health PersonnelChemotherapy, AdjuvantChoice BehaviorClinical Decision-MakingFemaleHumansMaleMiddle AgedNephrectomybenefit-risk assessmentdiscrete-choice experimentpreferencesRenal cell carcinomashared decision-making

Identifiers

PMID39945436
PMCPMC11916416

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.